PanGen Biotech and International Vaccine Institute (IVI) have signed a memorandum of understanding on their cooperation in the development of a recombinant coronavirus vaccine containing a specific protein subunit of the virus.

Under the MOU, the two will exchange information and technology for vaccine development and cooperate in the supply of necessary research materials, the Kosdaq-listed company said on Thursday.

PanGen shares jumped by their daily 30 percent limit to 11,650 won ($10.06) upon the news.

The two also agreed to explore promising shot candidates subject to commercial development or out-licensing.

PanGen is separately developing a subunit coronavirus vaccine based on its CHO-TECH platform technology for mass production in partnership with CHA Vaccine Institute. The company is eyeing for preclinical and clinical production of vaccine materials at its GMP-grade site.

IVI headquartered in Seoul is an independent, non-profit international organization established under the Vienna Convention and by the United Nations Development Programme (UNDP). It plays a role as a research arm to promote the research, development and distribution of vaccines to be used in the global public health environment.

By Pulse

[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]